KRSANasdaqPharmaceutical PreparationsUS GAAP · USD

Korsana Biosciences, Inc.

Korsana Biosciences, Inc. is a U.S.-based biotechnology company focused on discovering and developing novel therapies for neurodegenerative diseases. Its business centers on research-stage drug programs and related partnering, licensing, and asset transactions around its therapeutic candidates.

Ask about the company
Revenue2.1m USD
+3.7 %y/y
Operating profit (EBIT)-5.0m USD
−37.1 %y/y
EBIT margin-239.8%
−58.4 ppy/y
Net income-3.5m USD
−15.4 %y/y

Fiscal year 2025 · change from previous year

Development 2020–2025

-100-80-60-40-20020m USD2020: 2.3 m USD2020: EBIT -81 m USD20202021: 3.9 m USD2021: EBIT -55 m USD20212022: 1.6 m USD2022: EBIT -44 m USD20222023: 0.00 m USD2023: EBIT -13 m USD20232024: 2.0 m USD2024: EBIT -3.6 m USD20242025: 2.1 m USD2025: EBIT -5.0 m USD20252.1-5.0
RevenueOperating profit (EBIT)
Ask Clarifo about Korsana Biosciences, Inc.

Business

Share of revenue
Therapeutic R&D70 %

Research and development of drug candidates for neurodegenerative diseases.

Licensing and option income20 %

Fees from options or licenses tied to specific therapeutic programs.

Asset and materials transactions10 %

Sales of development materials or other program-related assets.

Products

Reported · share of revenue
87.5%12.5%FY2024100 %
  • License Agreement87.5 %
  • License12.5 %

Source: 10-K/A FY2024, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.

Customers

Korsana sells primarily to pharmaceutical and biotechnology counterparties that evaluate, license, or acquire rights to its therapeutic programs. It also transacts with development partners and strategic investors who fund or support specific drug assets. The end market is specialty life sciences, where buyers are focused on pipeline optionality, scientific data, and access to novel mechanisms in neurodegeneration.

Pharmaceutical licensees

Buy option or license rights to Korsana's therapeutic candidates for internal development.

Biotechnology collaborators

Enter partnering or asset transactions tied to specific research programs and data packages.

Strategic investors

Provide capital through financing transactions linked to corporate development or merger activity.

Strategy

Korsana’s strategy is to advance neuroscience drug candidates while using partnering, licensing, and asset transactions to support development. The company also relies on external financing and strategic transactions to fund its pipeline and extend operating runway. This model makes scientific progress and deal execution central to value creation.

Advance neurodegenerative disease pipelineMedium term

Clinical and preclinical progress is the core driver of biotech value.

Secure partnering and licensing incomeShort term

Non-dilutive deal flow can fund research and validate assets.

Access external capitalShort term

Research-stage companies typically need financing to sustain operations.

Geography

Korsana is based in the United States and operates as a U.S. biotechnology company. The available disclosures do not break out revenue by geography, and the company’s commercial activity appears tied to U.S.-based corporate, financing, and partnering transactions. Its exposure is therefore driven more by U.S. capital markets and regulatory oversight than by international sales diversification.

Risks

Korsana faces classic early-stage biotech risks tied to clinical development uncertainty, financing needs, and the ability to complete strategic transactions. The company also has specific execution risk around the proposed merger and related financing, which could affect funding access and business continuity. As with most pharmaceutical development companies, regulatory outcomes, scientific failure, and partner dependence can materially alter value.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Insufficient capital to fund operations1Failure to complete the proposed merger2Clinical and scientific development failure3Dependence on third-party counterparties4
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Insufficient capital to fund operationsImpact: CriticalLikelihood: High

    The business expects to need additional funding and has a limited operating runway.

    Exposure: Cash runway and dilution

  2. Failure to complete the proposed mergerImpact: HighLikelihood: Medium

    The company disclosed that delays or failure to complete the merger could materially affect results and stock price.

    Exposure: Corporate transaction and financing continuity

  3. Clinical and scientific development failureImpact: HighLikelihood: Medium

    Therapeutic candidates may not demonstrate the required safety or efficacy profile.

    Exposure: Pipeline programs

  4. Dependence on third-party counterpartiesImpact: MediumLikelihood: High

    Revenue from options, licenses, and asset sales depends on partner interest and timing.

    Exposure: Partnering and non-dilutive revenue

Ask Clarifo about Korsana Biosciences, Inc.

Accounting

Judgemental items
Revenue recognition for option and purchase agreements

Revenue depends on contract milestones, delivery, and reimbursement terms rather than recurring sales.

Impact: Can create quarter-to-quarter revenue volatility

R&D expense recognition

Research costs are expensed as incurred, so spend timing directly affects reported results.

Impact: High operating loss visibility

Capitalized prepayments for R&D

Nonrefundable advance payments are deferred until goods or services are received.

Impact: Affects balance sheet and near-term expense timing

Financing instruments and warrants

Private-company financing and pre-funded warrants may require complex classification and valuation.

Impact: Can affect equity, dilution, and fair value estimates

Similar listed companies

Publicly listed companies with a comparable business focus.

Korro Bio, Inc.

KRRO · Pharmaceutical Preparations

Neurogene Inc.

NGNE · Pharmaceutical Preparations

Pasithea Therapeutics Corp.

KTTA · Pharmaceutical Preparations

ProMIS Neurosciences Inc.

PMN · Pharmaceutical Preparations

Prothena Corporation plc

PRTA · Pharmaceutical Preparations

Serina Therapeutics, Inc.

SER · Pharmaceutical Preparations

Last updated: 28/09/2026

Korsana Biosciences, Inc. (KRSA) Revenue, Earnings & Financials 2025 – Clarifo